Pharmacological Approaches in Newborn Infants with Hypoxic Ischemic Encephalopathy

摘要: Despite marked improvements in perinatal practice, neonatal hypoxic-ischemic encephalopathy (HIE) remains one of the major causes acute mortality and chronic neurologic disability infants children. Several new therapeutic approaches aiming at this condition have been used last decade, including hypothermia many pharmacological agents. Therapeutic remarkably reduces death neurological impairment, has therefore rapidly become standard therapy for full-term newborn with moderate-to-severe HIE. However, despite these promising outcomes hypothermia, approximately 50% treated an adverse outcome. Therefore, there exists urgent need other treatment options. A mechanistically driven approach to HIE resulted development drugs that are potent antagonists specific steps cascades molecular reactions HI injury. This review provides overview neuroprotection may be clinical practice. Although several found effective preclinical evaluations, such ineffective human trials. Failure attributed factors as complex pathology neonates, inevitable delays initiation side effects drugs. Moreover, interfere only step cascades, while multiple biochemical put motion simultaneously. neuroprotective strategies deal cascades. Research is now being focused on act synergistically or additively hope combination might augment neuroprotection.